FDA Approves Eli Lilly's Foundayo, 2nd New Oral GLP-1 Drug
Updated
Updated · USA TODAY · Jun 26
FDA Approves Eli Lilly's Foundayo, 2nd New Oral GLP-1 Drug
3 articles · Updated · USA TODAY · Jun 26
Summary
April 1, 2026 marked FDA approval of Foundayo, Eli Lilly’s oral GLP-1 medicine, making it the second newly approved pill in a class first marketed as injections.
GLP-1 drugs were developed for Type 2 diabetes and obesity-related disease, but their weight-loss effects have driven broad consumer demand and expanded use.
More than 30 million U.S. adults were estimated to have used a GLP-1 in 2025, underscoring the commercial and clinical significance of an oral option.
Gallup said the U.S. adult obesity rate fell to 37.0% in 2025 from a 39.9% peak in 2022 — equal to 7.6 million fewer obese adults.
Researchers are already testing broader uses in heart failure, chronic liver disease, obstructive sleep apnea and substance abuse, while stronger formulations and months-long implants are expected.
Are patent royalties for new therapies becoming a greater barrier to public health than the diseases they are designed to cure?
As medicine pioneers 3D-printed organs, is it widening the gap between what is technologically possible and what is publicly accessible?
With AI now writing medical notes, who is ultimately liable when an algorithm's error leads to a patient's harm?
Foundayo’s 2026 FDA Approval: A New Era for Oral GLP-1 Weight Management and Patient Access
Overview
In April 2026, the FDA approved Eli Lilly's Foundayo (orforglipron) as the second oral GLP-1 receptor agonist for weight management, following Novo Nordisk's oral Wegovy. This rapid succession of approvals highlights a growing demand for more convenient obesity treatments and a shift away from injectables. Foundayo's approval was notably expedited through the FDA’s Commissioner’s National Priority Voucher (CNPV) program, which aims to accelerate access to important therapies for major public health needs. As a result, patients now have a new, easier-to-use option for weight management, reflecting the evolving landscape of obesity care.